Advertisement

Topics

Eli Lilly Drug Fails in Lung Cancer, Stalling Oncology Strategy

10:43 EDT 10 Oct 2017 | Xconomy

A cancer drug that Eli Lilly was positioning as a challenger to similar drugs from rivals Pfizer and Novartis has failed a late-stage clinical trial in lung cancer. Indianapolis-based Lilly (NYSE: LLY) said Tuesday that its drug, abemaciclib (Verzenio), did not meet the Phase 3 study’s main goal of improving overall survival in patients who […]

Original Article: Eli Lilly Drug Fails in Lung Cancer, Stalling Oncology Strategy

NEXT ARTICLE

More From BioPortfolio on "Eli Lilly Drug Fails in Lung Cancer, Stalling Oncology Strategy"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...